Want to see TSE:VM full AI Analyst Report?
Top Page
Voyageur Pharmaceuticals
(VM)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$0.15
▼(-10.59% Downside)
Action:Reiterated
Date:07/27/26
The score is held down primarily by weak financial performance—large losses, extremely negative margins, and continued cash burn despite improving revenue—alongside an unsupportive valuation signal from a negative P/E. Technicals are only mildly positive (price above 50/100-day averages) but lack confirming momentum indicators, limiting their offsetting impact.
Positive Factors
Low Leverage
Very low debt reduces financial risk and interest burden, giving management flexibility to prioritize product qualification and commercial ramp without near-term debt servicing constraints. This structural balance sheet strength supports surviving development timelines and negotiating non-debt funding.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow means the company is consuming cash to run core operations. This structural cash burn necessitates external financing or dilution, constrains investment in processing capacity and regulatory clearance, and limits ability to scale commercially.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt reduces financial risk and interest burden, giving management flexibility to prioritize product qualification and commercial ramp without near-term debt servicing constraints. This structural balance sheet strength supports surviving development timelines and negotiating non-debt funding.
Read all positive factors
Voyageur Pharmaceuticals (VM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$37.35M
Dividend YieldN/A
Average Volume (3M)72.03K
Price to Earnings (P/E)―
Beta (1Y)-0.19
Revenue GrowthN/A
EPS Growth-49.66%
CountryCA
Employees49
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding226,342,350
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Voyageur Pharmaceuticals Business Overview & Revenue Model
Company Description
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from brom...
How the Company Makes Money
Publicly available, company-specific detail on Voyageur Pharmaceuticals’ realized revenue model (e.g., current commercial sales volumes, pricing, customer mix, or signed offtake contracts) is null. Based on its stated business focus, the company’s...
Voyageur Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.24K | 11.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.17M | -1.22M | -1.57K | -2.19K | -2.91K | -2.25K |
| EBITDA | -3.80M | -3.53M | -1.71M | -1.22M | -1.75M | -2.05M |
| Net Income | -3.80M | -3.53M | -1.71M | -1.40M | -1.75M | -2.05M |
Balance Sheet | ||||||
| Total Assets | 3.22M | 3.11M | 2.60M | 2.16M | 2.10M | 2.57M |
| Cash, Cash Equivalents and Short-Term Investments | 441.87K | 267.05K | 165.57K | 2.08K | 31.56K | 812.97K |
| Total Debt | 40.00K | 40.00K | 40.00K | 40.00K | 25.52K | 42.08K |
| Total Liabilities | 2.81M | 1.85M | 2.15M | 727.88K | 630.83K | 660.64K |
| Stockholders Equity | 408.20K | 1.25M | 449.96K | 1.44M | 1.46M | 1.91M |
Cash Flow | ||||||
| Free Cash Flow | -1.01M | -2.89M | -302.29K | -991.25K | -2.00M | -2.09M |
| Operating Cash Flow | -1.01M | -2.89M | -302.29K | -991.25K | -1.72M | -1.65M |
| Investing Cash Flow | -272.31K | -270.02K | -165.96K | -174.72K | -274.15K | -432.08K |
| Financing Cash Flow | 1.35M | 3.26M | 631.73K | 1.14M | 1.21M | 2.90M |
Voyageur Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | C$33.99M | -3.62 | -23.55% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$37.35M | -7.83 | -313.14% | ― | ― | -49.66% | |
46 Neutral | C$33.79M | -18.70 | -3.16% | ― | 16.66% | -1007.41% | |
45 Neutral | C$10.63M | -3.23 | 35.85% | ― | -37.11% | 64.44% | |
45 Neutral | C$10.12M | -5.01 | -31.76% | ― | -17.50% | -120.67% | |
41 Neutral | C$16.35M | -4.25 | -116.09% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:VM
Voyageur Pharmaceuticals
0.17
>-0.01
-2.86%
TSE:LABS
MediPharm Labs
0.08
>-0.01
-6.25%
TSE:PCLO
PharmaCielo
0.06
0.02
33.33%
TSE:ROMJ
Rubicon Organics
0.46
-0.08
-14.81%
TSE:AVCN
Avicanna
0.13
-0.14
-51.85%
TSE:INNO
InnoCan Pharma
2.30
-12.33
-84.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.